About 150 children tested positive for influenza across Seattle Children’s system in two weeks, compared with roughly 10 in the same period last year—an unusually early rise that has put pediatric clinicians and public-health teams across the West on alert before the traditional respiratory-virus season is fully underway.

The increase is not yet evidence of a severe nationwide flu season. The latest CDC report, covering the week ending September 26, still classified national influenza activity as low. Yet clinical laboratories reported that 3.4% of respiratory specimens were positive for influenza, up from 1.8% two weeks earlier. That national average also masks faster growth in parts of Washington, Nevada, Alaska, California and Hawaii.

The contrast is the central public-health issue: localized indicators are moving quickly while the national burden remains modest. The pattern may fade, or it may be an early warning that gives health systems and families less preparation time than usual. The evidence supports vigilance, not a prediction of how severe the winter will become.

An early regional signal

The most striking data come from Washington. Seattle Children’s told The Washington Post that the current volume of positive tests is closer to what the hospital system normally sees in early December. The share of tests coming back positive has also risen, suggesting that the increase reflects broader community transmission rather than testing more children.

State surveillance points in the same direction. Washington’s health dashboard, updated September 30, showed acute respiratory illness accounting for 11% of emergency-department visits in the week ending September 26, up from 8.2% three weeks earlier. King County recorded 233 flu-associated emergency visits in the week ending September 19, compared with 31 in the comparable week a year earlier.

Those figures are meaningful, but they are not interchangeable. A positive laboratory test confirms influenza, while an emergency-department diagnosis depends on clinical coding and may be revised. The broader acute-respiratory category includes COVID-19, influenza, respiratory syncytial virus and other illnesses. Washington also warns that its most recent hospitalization data are incomplete because reporting can lag by several weeks.

Nevada offers a different signal. The health district reported on September 24 that a Clark County man in his 50s with underlying conditions had died from flu, the region’s first flu-related death of the season. One death cannot establish a trend, and local officials said activity remained low. It nevertheless shows that severe outcomes can occur before surveillance systems register widespread transmission.

Nationally low does not mean locally quiet

The CDC’s Week 38 report helps reconcile the apparently conflicting picture. Nationally, 1.7% of outpatient visits involved fever plus cough or sore throat, a measure known as influenza-like illness. But that measure is not laboratory-confirmed flu and can capture several pathogens. The report also notes that state health departments may hold more complete or timely data than the federal system because reporting streams differ.

Federal modeling is designed to detect direction before burden becomes high. The CDC’s trend estimates use emergency-department diagnoses to estimate whether infections are growing. Such estimates can flag change earlier than hospitalization or death counts, but they remain model-based and are revised as data accumulate. A rising trend describes momentum, not the ultimate height of the season.

Geographic unevenness is also normal. Influenza can accelerate in one metropolitan area while remaining sparse elsewhere, especially near the transition from summer to fall. Travel, school reopening, weather and population immunity may all influence timing. None of those explanations has been established as the cause of this year’s Western rise.

Why H1N1 is drawing attention

Early subtyping in Washington has found A(H1N1)pdm09 predominating. That matters because last season was dominated by H3N2, potentially leaving less recent population immunity against H1N1. It does not mean the virus is novel: H1N1pdm09 has circulated seasonally since the 2009 pandemic and is included in the current vaccine.

The WHO composition recommendation for 2026–27 called for an A/Missouri/11/2025-like H1N1 virus in both egg-based and non-egg vaccines. The other components target an H3N2 strain and a B/Victoria lineage virus. Those selections are made months in advance so manufacturers can produce doses before the season begins.

Whether the vaccine proves well matched cannot be determined from early case counts. Laboratories must genetically and antigenically characterize circulating viruses, and effectiveness estimates require enough vaccinated and unvaccinated patients with comparable illness to support analysis. Those results typically arrive after transmission is established.

Last season’s data illustrate why effectiveness should not be reduced to a single number. A CDC analysis using three test-negative surveillance networks estimated 38% to 41% protection against flu-related outpatient visits in children and adolescents and 41% protection against hospitalization. Estimates vary by age, outcome, strain and study design, and observational analyses can retain residual differences between vaccinated and unvaccinated groups.

Vaccination timing meets an earlier wave

The timing creates a practical problem. Federal guidance generally treats September and October as appropriate months for most people to receive a flu vaccine, with the goal of building protection before widespread winter transmission. It takes roughly two weeks for an immune response to develop, so an early local wave can narrow that buffer.

The CDC’s current clinical guidance continues to recommend annual vaccination for nearly everyone 6 months and older, with rare exceptions. The agency says no one product is preferred for most people when more than one age-appropriate vaccine is available. Adults 65 and older are the exception: high-dose, adjuvanted or recombinant vaccines are preferentially recommended when available.

Timing is not identical for everyone. The same guidance says most adults—particularly those 65 and older—and people in the first or second trimester of pregnancy generally should avoid July or August vaccination because protection can wane. Vaccination in July or August can be considered during the third trimester to help protect infants too young to receive a flu vaccine. Children who need two doses should start earlier because the doses must be separated.

Those are population-level recommendations, not individualized medical advice. People with a history of severe vaccine reactions or questions about pregnancy, immunocompromise or age-specific products should use a clinician or pharmacist to apply the guidance to their circumstances.

What the evidence says—and cannot yet say

The 2024–25 season provides a reminder of influenza’s potential burden. The CDC’s final estimate attributes about 51 million illnesses, 23 million medical visits, 710,000 hospitalizations and 45,000 deaths to flu. The agency had received reports of 290 pediatric deaths as of February 2026, the highest reported total for a regular flu season since pediatric deaths became nationally reportable.

Those burden estimates are produced with statistical models because many people are never tested and influenza may not be listed on death certificates. They should be understood as ranges distilled into central estimates, not literal case-by-case counts. Similarly, a cluster of early pediatric cases in Seattle does not prove that the 2026–27 season will match last year’s toll.

The near-term healthcare implication is narrower and more defensible. Western hospitals and clinics may need to adjust respiratory-testing supplies, staffing and infection-control messaging earlier than usual. Public-health agencies should continue publishing age, subtype, hospitalization and geographic data quickly enough to distinguish a short regional pulse from a sustained national wave.

For now, the strongest conclusion is that flu has arrived early in several Western communities and that the window between vaccination and exposure may be shorter there. The next several weekly reports—not a single dramatic statistic—will show whether the pattern broadens, stabilizes or recedes.